• Bayer flagged new clinical data across cardiac amyloidosis and heart failure programs scheduled for presentation at HFSA 2026 in Phoenix.
• Late-breaking results from the Phase III REVEAL study assessed whether investigational PET tracer iodine-124 evuzamitide can detect cardiac amyloidosis reliably.
• Additional disclosures will outline designs for three ongoing finerenone heart-failure trials, signaling continued investment in label expansion and differentiation.
• Two real-world analyses will review how often steroidal mineralocorticoid receptor antagonists are started and maintained in US heart-failure care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief via Business Wire (Ref. ID: 202610081500BIZWIRE_USPR_____20261007_BW322202) on October 08, 2026, and is solely responsible for the information contained therein.